All In Biotech

NDA 211243 · Janssen Pharms

Spravato

Esketamine Hydrochloride · Nasal

Breakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 5, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

321

30 Phase 3, 49 recruiting

FAERS reports

18,798

13,122 serious, 736 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration. ( 5.1 , 5.2 , 5.3 ) Potential for abuse and misuse. Consider the risks and benefits of prescribing SPRAVATO prior to using in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse. ( 5.4 ) SPRAVATO is only available through a restricted program called the SPRAVATO REMS. ( 5.5 ) Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all...

What it is approved for

From the label in effect Sep 22, 2026.

SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant SPRAVATO is a non-competitive N -methyl D -aspartate (NMDA) receptor antagonist indicated for the treatment of: Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant. ( 1 ) Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant. ( 1 ) Limitations of Use: The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. ( 1 ) SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established. ( 1 ) Limitations of Use The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated [see Clinical Studies (14.2) ] . Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established.

Mechanism: Esketamine, the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N -methyl- D -aspartate (NMDA) receptor, an ionotropic glutamate receptor. The mechanism by which esketamine exerts its antidepressant effect is unknown. The major circulating metabolite of esketamine (noresketamine) demonstrated activity at the same receptor with less affinity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 17, 2025 Supplement 16 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Jul 31, 2020 Supplement 4 · Efficacy Breakthrough therapyLetterLabelReview
  • Mar 5, 2019 Original approval · Type 2 - New Active Ingredient · priority review Breakthrough therapyLabelLetterREMS
1 products under this application
  • SPRAVATO · ESKETAMINE HYDROCHLORIDE EQ 28MG BASE · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Esketamine" as an intervention, any sponsor and status, largest first.

All 321 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dissociation3,903
  • sedation2,816
  • suicidal ideation1,446
  • drug ineffective1,134
  • nausea1,006
  • depression956
  • hypertension917
  • product dose omission issue852
  • hospitalisation850
  • anxiety775
  • vomiting764
  • dizziness670

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20173
20181
2019677
20201,004
20211,249
20221,463
20232,111
20243,262
20256,094
20262,933

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Spravato (Esketamine HCl)

2024 spending

$128M

Beneficiaries

5,542

84,544 claims

Per beneficiary

$23,121

$394.89 per unit

View as table
YearSpending
2020$21,836,746
2021$32,871,804
2022$49,999,095
2023$80,470,297
2024$128,139,293

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 636 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.